Oasmia publishes Interim Report for May - Oct
Oasmia Pharmaceutical AB (publ)
Interim report for the period May 1 - Oct 31, 2009
THE NEXT PHARMACEUTICAL CANDIDATE, DOXOPHOS VET, ENTERS CLINICAL PHASE
THE PERIOD IN BRIEF May - Oct 2009
• Net sales for the group amounted to TSEK 24 911 (59 785)
• Operating income amounted to TSEK 1 905 (16 993)
• Net income after tax amounted to TSEK 21 (17 086)
• Earnings per share amounted to SEK 0,00 (SEK 0,51)
• Comprehensive income amounted to TSEK 21 (17 086)
• Oasmia and Abbott Laboratories announced a multi-year agreement for distribution of Paccal® Vet for treatment of cancer in dogs in the USA and Canada.
• Patient enrollment for a pivotal international Phase III study with the pharmaceutical candidate Paccal® Vet was successfully completed.
• A new share issue with preferential rights for current shareholders was made and was fully subscribed.
THE SECOND QUARTER Aug - Oct 2009
• Net sales for the group amounted to TSEK 253 (15 180)
• Operating income amounted to TSEK -8 719 (-7 131)
• Net income after tax amounted to TSEK -9 365 (-7 042)
• Earnings per share amounted to TSEK -0,27 (-0,21 kr)
• Comprehensive income amounted to TSEK -9 365 (-7 042)
EVENTS AFTER CLOSING DAY
• The pharmaceutical candidate Doxophos Vet enters clinical phase after promising preclinical study results. The clinical program is planned to start in the beginning of 2010.
• A private placement for a limited number of institutional investors and other larger investors was carried out and was fully subscribed.
The report is available in its entirety in PDF-format here.
